Prognostic utility of the CALLY index in metastatic melanoma: building a nomogram for Patients on Anti-PD-1 therapy
The CALLY index is a cost-effective and independent prognostic biomarker that can aid in risk stratification and guide treatment decisions in patients with metastatic melanoma receiving anti-PD-1 therapy.
Authors
- Haydar Çağatay Yüksel (ORCID: https://orcid.org/0000-0001-8857-2983)
- Damla Günenç (ORCID: https://orcid.org/0000-0002-7592-2021)
- Burçak Karaca (ORCID: https://orcid.org/0000-0003-2638-1625)
- Caner Acar (ORCID: https://orcid.org/0000-0002-9782-6807)
- Fatma Pınar Açar (ORCID: https://orcid.org/0009-0000-2749-8732)
- Gökhan Şahin (ORCID: https://orcid.org/0000-0003-1478-9383)
Institutions
- Ege University (TR)
Publication Details
- Journal
- Clinical & Translational Oncology
- Published
- 2025-03-16
- DOI
- https://doi.org/10.1007/s12094-025-03888-z
- Citations
- 10
- Primary Topic
- Inflammatory Biomarkers in Disease Prognosis
- Type
- article
- Field-Weighted Citation Impact
- 10.45
Funders
- Ege Üniversitesi